A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

NCT06095089 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

355

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: JNJ-78278343
DRUG: JNJ-87189401
DRUG: Apalutamide
DRUG: Lutetium Lu-177 Vipivotide Tetraxetan
DRUG: JNJ-101556143

Sponsor

Janssen Research & Development, LLC